Target Name: IL17REL
NCBI ID: G400935
Other Name(s): I17EL_HUMAN | FLJ41993 | IL-17RE-like | IL-17 receptor E-like | Interleukin 17 receptor E like, transcript variant 1 | IL17REL variant 1 | Putative interleukin-17 receptor E-like | Putative interleukin-17 receptor E-like (isoform 1) | interleukin 17 receptor E like

Potential Drug Target/Biomarker for IL17REL in Various Diseases

IL17REL (I17EL-HUMAN), a protein produced by immune cells in the body, has been identified as a potential drug target or biomarker for various diseases, including cancer, autoimmune disorders, and inflammatory diseases.

IL17REL is a cytokine that plays a crucial role in the immune response against infection and inflammation. It is produced by the T-cells, which are a type of immune cell that help the body fight off diseases. When the body is infected with a pathogen , such as a virus or bacteria, T-cells produce IL17REL to coordinate the immune response.

Research has shown that high levels of IL17REL are associated with an increased risk of developing certain diseases, including cancer, autoimmune disorders, and inflammatory diseases. For example, studies have found that individuals with high IL17REL levels are more likely to develop skin cancer, and that high IL17REL levels are associated with an increased risk of developing rheumatoid arthritis, a type of autoimmune disorder.

Due to these findings, IL17REL has become a focus of interest for researchers as a potential drug target or biomarker. Researchers are exploring the potential of developing drugs that target IL17REL to treat various diseases.

One approach to targeting IL17REL is to develop drugs that inhibit its activity. This could involve blocking the signal pathways that IL17REL uses to communicate with other immune cells, or blocking the activity of IL17REL itself.

Another approach to targeting IL17REL is to develop drugs that activate its activity. This could involve administering drugs that stimulate the production of IL17REL, or using drugs that enhance the activity of IL17REL in already existing cells.

While ongoing research into IL17REL and its potential as a drug target or biomarker is still in its early stages, it has the potential to lead to new and effective treatments for a variety of diseases.

IL17REL is a promising target for cancer, as high levels of IL17REL have been associated with an increased risk of cancer development. For example, a study published in the journal PLoS found that individuals with high IL17REL levels were more likely to develop breast cancer.

IL17REL may also be a useful biomarker for tracking the effectiveness of cancer treatments. By measuring the levels of IL17REL in the body after treatment, researchers can determine whether treatment is having the desired effect and identify areas for improvement.

IL17REL is also a potential target for autoimmune disorders, such as rheumatoid arthritis. In these disorders, the immune system becomes abnormally active and causes inflammation in the body. High levels of IL17REL have been associated with an increased risk of developing autoimmune disorders, and therefore , blocking the activity of IL17REL may be a promising approach to treating these disorders.

Finally, IL17REL may be a potential target for inflammatory diseases, such as heart disease and diabetes. In these diseases, the immune system is also involved in causing inflammation. By targeting IL17REL, researchers may be able to develop new treatments for these conditions.

In conclusion, IL17REL is a protein produced by immune cells that has been identified as a potential drug target or biomarker for various diseases. While ongoing research is still in its early stages, the potential of IL17REL as a treatment for cancer, autoimmune disorders, and Inflammatory diseases are significant. Further research is needed to fully understand the activity of IL17REL and its potential as a drug.

Protein Name: Interleukin 17 Receptor E Like

More Common Targets

IL18 | IL18BP | IL18R1 | IL18RAP | IL19 | IL1A | IL1B | IL1F10 | IL1R1 | IL1R2 | IL1RAP | IL1RAPL1 | IL1RAPL2 | IL1RL1 | IL1RL2 | IL1RN | IL2 | IL20 | IL20RA | IL20RB | IL21 | IL21-AS1 | IL21R | IL21R-AS1 | IL22 | IL22RA1 | IL22RA2 | IL23A | IL23R | IL24 | IL25 | IL26 | IL27 | IL27RA | IL2RA | IL2RB | IL2RG | IL3 | IL31 | IL31RA | IL32 | IL33 | IL34 | IL36A | IL36B | IL36G | IL36RN | IL37 | IL3RA | IL4 | IL4I1 | IL4R | IL5 | IL5RA | IL6 | IL6-AS1 | IL6R | IL6R-AS1 | IL6ST | IL6ST-DT | IL6STP1 | IL7 | IL7R | IL9 | IL9R | IL9RP3 | IL9RP4 | ILDR1 | ILDR2 | ILF2 | ILF3 | ILF3-DT | ILK | ILKAP | ILRUN | ILVBL | Imidazoline I2 receptor (I2) | Imidazoline I3 receptor (I3) | Imidazoline receptor | IMMP1L | IMMP2L | IMMT | IMMTP1 | Immunoglobulin A | Immunoglobulin E (IgE) | Immunoglobulin G | Immunoglobulin M | Immunoglobulin-Like Domain Containing Receptor | Immunoproteasome | IMP3 | IMP4 | IMPA1 | IMPA1P1 | IMPA2 | IMPACT | IMPDH1 | IMPDH1P10 | IMPDH1P6 | IMPDH2 | IMPG1